Cargando…
Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances
Small cell neuroendocrine carcinoma of the cervix (SCNECC) is an uncommon but aggressive uterine malignancy, the cause of which is generally associated with human papillomavirus (HPV) infection. A lack of clinical trials and evidence-based treatment guidelines poses therapeutic challenges to this ra...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chang Gung University
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522988/ https://www.ncbi.nlm.nih.gov/pubmed/37467967 http://dx.doi.org/10.1016/j.bj.2023.100633 |
_version_ | 1785110469463244800 |
---|---|
author | Chao, Angel Wu, Ren-Chin Lin, Chiao-Yun Chang, Ting-Chang Lai, Chyong-Huey |
author_facet | Chao, Angel Wu, Ren-Chin Lin, Chiao-Yun Chang, Ting-Chang Lai, Chyong-Huey |
author_sort | Chao, Angel |
collection | PubMed |
description | Small cell neuroendocrine carcinoma of the cervix (SCNECC) is an uncommon but aggressive uterine malignancy, the cause of which is generally associated with human papillomavirus (HPV) infection. A lack of clinical trials and evidence-based treatment guidelines poses therapeutic challenges to this rare tumor. At present, published data remain limited to case series and case reports. While clinical management has traditionally followed those of small cell neuroendocrine (SCNE) lung cancer relying on surgery, chemoradiation, and systemic chemotherapy, the prognosis remains dismal. Immune checkpoint inhibitors (ICIs), such as monoclonal antibodies that target programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1), atezolizumab and durvalumab have proven effective in extensive-stage SCNE lung cancer. Moreover, pembrolizumab has also proven beneficial effects when added onto chemotherapy in metastatic and recurrent HPV-associated non-SCNE cervical cancer. It holds promise to use ICIs in combination with chemoradiation to improve the clinical outcomes of patients with SCNECC. Future advances in our understanding of SCNECC biology – associated with the study of its genomic and molecular aberrations as well as knowledge from SCNE of lung and other extrapulmonary sites– would be helpful in discovering new molecular targets for drug development. Collaborative efforts and establishment of a SCNECC-specific biobank will be essential to achieve this goal. |
format | Online Article Text |
id | pubmed-10522988 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Chang Gung University |
record_format | MEDLINE/PubMed |
spelling | pubmed-105229882023-09-28 Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances Chao, Angel Wu, Ren-Chin Lin, Chiao-Yun Chang, Ting-Chang Lai, Chyong-Huey Biomed J Review Article Small cell neuroendocrine carcinoma of the cervix (SCNECC) is an uncommon but aggressive uterine malignancy, the cause of which is generally associated with human papillomavirus (HPV) infection. A lack of clinical trials and evidence-based treatment guidelines poses therapeutic challenges to this rare tumor. At present, published data remain limited to case series and case reports. While clinical management has traditionally followed those of small cell neuroendocrine (SCNE) lung cancer relying on surgery, chemoradiation, and systemic chemotherapy, the prognosis remains dismal. Immune checkpoint inhibitors (ICIs), such as monoclonal antibodies that target programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1), atezolizumab and durvalumab have proven effective in extensive-stage SCNE lung cancer. Moreover, pembrolizumab has also proven beneficial effects when added onto chemotherapy in metastatic and recurrent HPV-associated non-SCNE cervical cancer. It holds promise to use ICIs in combination with chemoradiation to improve the clinical outcomes of patients with SCNECC. Future advances in our understanding of SCNECC biology – associated with the study of its genomic and molecular aberrations as well as knowledge from SCNE of lung and other extrapulmonary sites– would be helpful in discovering new molecular targets for drug development. Collaborative efforts and establishment of a SCNECC-specific biobank will be essential to achieve this goal. Chang Gung University 2023-10 2023-07-17 /pmc/articles/PMC10522988/ /pubmed/37467967 http://dx.doi.org/10.1016/j.bj.2023.100633 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Article Chao, Angel Wu, Ren-Chin Lin, Chiao-Yun Chang, Ting-Chang Lai, Chyong-Huey Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances |
title | Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances |
title_full | Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances |
title_fullStr | Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances |
title_full_unstemmed | Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances |
title_short | Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances |
title_sort | small cell neuroendocrine carcinoma of the cervix: from molecular basis to therapeutic advances |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522988/ https://www.ncbi.nlm.nih.gov/pubmed/37467967 http://dx.doi.org/10.1016/j.bj.2023.100633 |
work_keys_str_mv | AT chaoangel smallcellneuroendocrinecarcinomaofthecervixfrommolecularbasistotherapeuticadvances AT wurenchin smallcellneuroendocrinecarcinomaofthecervixfrommolecularbasistotherapeuticadvances AT linchiaoyun smallcellneuroendocrinecarcinomaofthecervixfrommolecularbasistotherapeuticadvances AT changtingchang smallcellneuroendocrinecarcinomaofthecervixfrommolecularbasistotherapeuticadvances AT laichyonghuey smallcellneuroendocrinecarcinomaofthecervixfrommolecularbasistotherapeuticadvances |